Disclosure: Dr. Maitra reports Thrive Earlier Detection has licensed an invention from Johns
Hopkins University in which Dr. Maitra is listed as an inventor. The focus of the license is on …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Introduction: Antibodies or fusion proteins termed biologics allow the targeted therapy of
diseases. Many of these agents have proven superior efficacy and safety to conventional …

Background Antibodies targeting interleukin (IL)-23 and IL-17A effectively treat moderate-to-
severe psoriasis. ECLIPSE is the first comparator study of an IL-23p19 inhibitor …

The emergence of a new acute respiratory syndrome Coronavirus 2 (SARS‐CoV‐2), the
cause of the 2019‐nCOV disease (COVID‐19), has caused a pandemic and a global health …

Objective To evaluate the effect of secukinumab, a fully human anti-interleukin-17A
monoclonal antibody, on efficacy, imaging outcomes, and safety through 4 years (208 …

The article presents a report on the updates in the European S3-Guideline on systemic
treatment of psoriasis vulgaris in cooperation with the European Academy of Dermatology …

After the World Health Organisation declared Coronavirus Disease 2019 (COVID-19) a
global pandemic on March 11, 2020, it became clear that health professionals worldwide …

Virtually all therapeutic proteins (biologics) elicit an immune response with the consequent
production of anti-drug antibodies (ADA). The majority of ADA to therapeutic monoclonal …

Objective Netakimab (NTK) is a humanised monoclonal antibody targeting interleukin-17A,
previously investigated in a phase 1 trial in healthy volunteers. Here, we report the results of …